Artiva appoints Daniel Baker to board; forms Clinical Strategy Committee

Artiva Biotherapeutics, Inc.

Daniel Baker, Ph.D. appointed as Class I director effective Jan 28, 2025; term expires at 2025 annual meeting.
Baker also named to Clinical Strategy Committee; Laura Bessen, Brian Daniels, Laural Stoppel appointed as members; Diego Miralles as chair.
Baker receives $40K annual board retainer and initial option for 27,500 shares; one-third vested immediately, remainder over two years.
Clinical Strategy Committee members get $7,500 annual retainer; chair receives $15,000.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel Baker

Class I Director

ARTV · Artiva Biotherapeutics, Inc.

Effective: 2025-01-28
Filed: January 29, 2025, 6:59 PM ET

On January 28, 2025, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel Baker, Ph.D. as (i) a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Baker was appointed as Class I Director at Artiva Biotherapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On January 28, 2025, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel Baker, Ph.D. as (i) a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders

View on SEC.gov

Artiva Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-010481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.